Epidemiology of Hepatitis C Virus in Iranian Thalassemic, Hemodialysis and Hemophiliac Patients: A Meta-Analysis Study
Abstract
Introduction: Hepatitis C is one of the most serious viral infections that cause chronic liver disease.
Objectives: The current study was conducted to estimate the pooled prevalence and geographical distribution of Hepatitis C Virus (HCV) in thalassemic, hemodialysis, and hemophiliac patients in Iran.
Evidence Acquisition: Articles were identified through international searching databases including PubMed, Scopus, Elsevier, Google Scholar, and Web of Science and Iranian scientific information database (SID), Health.barakatkns, IranDoc, Civilica and MagIran. We reviewed systematically all studies reporting the prevalence of HCV in thalassemic, hemodialysis, and hemophiliac patients. All studies conducted ELISA tests for the evaluation of HCV antibodies In this study meta-analysis method has been used to estimate the pooled prevalence.
Results: 270 records were identified by the electronic search, of which 151 studies were identified as relevant papers that were meta-analyzed for the pooled HCV prevalence. Overall, prevalence of HCV were 18.27%(15.99%-20.55%), 11.60%(9.98%-13.22%) and 45.16%(36.72%-53.60%) in thalassemic, hemodialysis and hemophiliac patients.
Conclusion: Concerning the high prevalence of HCV among hemophiliac patients, ongoing preventive actions for this group are recommended.
1. Simmonds, P., et al., Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. Journal of general virology, 1993. 74(11): p. 2391-2399.
2. who, World Health Organization. 2018.
3. Mohd Hanafiah, K., et al., Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology, 2013. 57(4): p. 1333-1342.
4. Jamali, R., Epidemiologic studies on viral hepatitis: a short review. Thrita, 2014. 3(1).
5. WHO, WHO. Global Hepatitis Report. 2017.
6. WHO, The epidemiology of hepatitis C virus in the World Health
Organization Eastern Mediterranean Region: Implications for strategic
action. Eastern Mediterranean Hepatitis C Virus Epidemiology
Synthesis Project. 2017.
7. Eissa, S., et al., National Cancer Institute experience in healthy Egyptian blood donors as regards blood group frequencies and seroprevalence of hepatitis b virus, hepatitis C Virus & HIV: 10 year evaluation. J Egypt Natl Canc Inst, 2007. 19(1): p. 71-6.
8. Chakrabarti, S., et al., Prevalence of anti HCV, HBsAg and HIV antibodies in high risk recipients of blood and blood products. Indian journal of public health, 2006. 50(1): p. 43-44.
9. Mirmomen, S., et al., Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med, 2006. 9(4): p. 319-23.
10. Kabir, A., S.-M. Alavian, and H. Keyvani, Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comparative Hepatology, 2006. 5(1): p. 4.
11. Remis, R., A study to characterize the epidemiology of hepatitis C infection in Canada: final report. Public Health Agency of Canada, 2002.
12. Makhloogh, A., et al., Hepatitis C prevalence in hemodialysis patients in Mazandaran, Iran: A survey by polymerase chain reaction and serological methods. Res J Biol Sci, 2008. 3(4): p. 265-268.
13. Alavian, S.-M., P. Adibi, and M.R. ZALI, Hepatitis C virus in Iran: Epidemiology of an emerging infection. 2005.
14. Khan, S., et al., Molecular epidemiology of HCV among health care workers of Khyber Pakhtunkhwa. Virology Journal, 2011. 8(1): p. 105.
15. L, F., et al., National surveillance of dialysis-associated diseases in the United States. 18, 2002. 1: p. 52-61.
16. Griveas, I., et al., Acute hepatitis C in patients receiving hemodialysis. Renal failure, 2007. 29(6): p. 731-736.
17. Mahmud, S., V. Akbarzadeh, and L.J. Abu-Raddad, The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. Scientific reports, 2018. 8(1): p. 150.
18. WHO, Global Hepatitis Report. 2017.
19. Behzadifar, M., et al., Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of virus eradication, 2019. 5(2): p. 116.
20. Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev.[Internet]. 2015; 4: 1.
21. Downes, M.J., et al., Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ open, 2016. 6(12): p. e011458.
22. Salehi-Vaziri, M., et al., Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepatitis monthly, 2016. 16(4).
23. Schafer, J.L., Analysis of incomplete multivariate data. 1997: Chapman and Hall/CRC.
24. Najimi Varzaneh, a. and m. Gholami Fesharaki, Prevalence of road traffic accidents in iran: A systematic review, gis and meta-analysis. Iranian red crescent medical journal (ircmj), 2018. 20(10): p. -.
25. Brown, L.D., T.T. Cai, and A. DasGupta, Interval estimation for a binomial proportion. Statistical science, 2001: p. 101-117.
26. Alavian, S.M., et al., Hepatitis C infection in the general population of Iran: a systematic review. Hepatitis Monthly, 2009. 9(3).
27. Mirminachi, B., et al., Update on the prevalence of hepatitis C virus infection among Iranian general population: a systematic review and meta-analysis. Hepatitis Monthly, 2017. 17(2).
28. Shamshirian, A., et al., Seroprevalence and geographical distribution of hepatitis C virus in Iranian patients with thalassemia: a systematic review and meta-analysis. Journal of Laboratory Medicine, 2019. 43(2): p. 45-55.
29. Behzadifar, M., H.A. Gorji, and N.L. Bragazzi, The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Archives of Virology, 2018. 163(5): p. 1131-1140.
30. Ashkani-Esfahani, S., S.M. Alavian, and M. Salehi-Marzijarani, Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World journal of gastroenterology, 2017. 23(1): p. 151.
31. ALAVIAN, S.M., et al., Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodialysis International, 2010. 14(3): p. 253-262.
32. Ghorbani, N.R., et al., Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2017. 22: p. 123-123.
33. G, s., et al., Prevalence of hepatitis C antibodies in hemophilic patients.
34. Ebrahimpour, S., M. YAGHOUBI, and V. Gharamaleki, Seropidemiological studies of hepatitis B and C in haemophiliacs in northwestern Iran. 1997.
35. L., M., Prevalence of hepatitis B , C and hiv in hemophilia patients. Seminar on Hereditary Hemorrhagic Diseases., 2004.
36. Khazaei, S., et al., The Epidemiology and Trend of Hepatitis C Infection in Hamadan Province: West of Iran, 2011-2016. VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2018. 24(3): p. 65-69.
37. Kashanchi Langarodi, M. and H. Abdolrahim Poorheravi, Prevalence of HCV among thalassemia patients in Shahid Bahonar Hospital, Karaj. The Scientific Journal of Iranian Blood Transfusion Organization, 2011. 8(2): p. 137-142.
38. Manuchehr, B., et al., Investigating the Infection with Viral Hepatitis C in Repeated Blood Transfusions in Ardabil Province, 2000. Ardabil Scientific Research Journal, 2003. 2(6).
39. Mashayekhi, Prevalence of blood transfusion induced hepatitis among patients with thalassemia in Tabriz. Hepatology International 2011. 5(1): p. 225.
40. Torabi, S., et al., Prevalence of hepatitis B and C in thalassemic patients of East Azarbaijan in 2003. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2005. 2(4): p. 115-122.
41. Valizadeh, N., et al., Seroprevalence of Hepatitis B, Hepatitis C and Human Immunodeficiency Viruses among Thalassemia Patients in West North of Iran. Iranian journal of pediatric hematology and oncology, 2015. 5(3): p. 145-148.
42. Reisi, N. and P. Raeisi, Molecular evaluation of HCV infection by RT-PCR test in major beta thalassemia patients, Hajar Hospital of Shahrekord. khoon, 2011.
43. Basirat nia, M., et al., Hepatitis C prevalence in Thalassemic children in Shahrekord. Journal of Shahrekord Uuniversity of Medical Sciences, 2000. 1(4): p. 13-18.
44. Karimi, M. and A.A. Ghavanini, Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. J Paediatr Child Health, 2001. 37(6): p. 564-6.
45. Hedayat, et al., Prevalence and Cause of Hepatitis B and C in Thalassemia and Hemophilia Patients in Fasa City 2003-2004. 6th GCC Medical Students Conference; 2009., 2009.
46. Ansari, H., H. Kamani, and A. Arbabi-Sarjo, Prevalence of hepatitis C and related factors among beta-thalassemia major patients in Southern Iran in 2005-2006. J Med Sci, 2007. 7(6): p. 997-1002.
47. Karimi, M. and A.A. Ghavanini, Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia, 2001. 31(3): p. 251-255.
48. Kashef, S., et al., Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. Int J Lab Hematol, 2008. 30(1): p. 11-6.
49. Yaghobi, R., et al., A study on the serologic and molecular prevalence of hepatitis G virus (HGV) and hepatitis C virus (HCV) infections in patients with thalassemia in Larestan of Iran. African Journal of Microbiology Research, 2012. 6(29): p. 5866-5870.
50. Akbari, A., et al., Hepatitis C Virus Antibody Positive Cases in Multitransfused Thalassemic Patients in South of Iran. Hepat Mon. 7(2): p. 63-66.
51. Jafroodi, M., et al., Trend in Prevalence of Hepatitis C Virus Infection among beta-thalassemia Major Patients: 10 Years of Experience in Iran. Int J Prev Med, 2015. 6: p. 89.
52. Ansar, M.M. and A. Kooloobandi, Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat, 2002. 9(5): p. 390-2.
53. Mansour-Ghanaei, F., et al., prevalence of Transfusion Transmitted Infections Among Patients with Major Thalassemia in Guilan, the North Province of Iran:# 1937. Transfusion, 2009. 49(10): p. 2258.
54. Kh. Oshvandi, P.D., B.S. M. Bakhshi, and B.S. F. Pourazizi, The Investigation of Blood Transfusion’s Complications of Thalassemic Patients in Educational Hospitals of Hamadan Medical Science University. Avicenna Journal of Nursing and Midfery Care, 2009. 17(12): p. 53-63.
55. Eghbalian, F. and A. Monsef, Study of Prevalence of Posttransfusion Infections in Hamadan Thalassemic Children. Avicenna Journal of Clinical Medicine, 2000. 7(3): p. 0-0.
56. Aminianfar, M., F. Khani, and I. Ghasemzadeh, Evaluation of hepatitis C, hepatitis B, and HIV virus Serology pandemic in thalassemia patients of Shahid Mohammadi Hospital of Bandar Abbas, Iran. Electronic physician, 2017. 9(3): p. 4014.
57. Ataei, B., et al., Prevalence of anti HCV infection in patients with Beta-thalassemia in isfahan-iran. Int J Prev Med, 2012. 3(Suppl 1): p. S118-23.
58. Kalantari, H., et al., Prevalence of hepatitis C virus, hepatitis B virus, human immunodeficiency virus and related risk factors among hemophilia and thalassemia patients In Iran. Archives of Clinical Infectious Diseases, 2011. 6(2): p. 82-84.
59. Kassaian, N., et al., Hepatitis C in Patients with Multi Blood Transfusion. Journal of Isfahan Medical School, 2011. 28.
60. Hariri, M., et al. Prevalence of hepatitis B, C and HIV markers in thalassemic and haemophilic patients in Isfahan, Iran, 2004. in Vox Sanguinis. 2008. WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
61. Naghavi, N., et al., Hepatitis C virus infection among haemophilia and thalassemia patients in Isfahan in 2005. Iranian Journal Of Infectious Diseases And Tropical Medicine, 2007. 11(35): p. 33-39.
62. Zahedi, M., et al., The prevalence of heptitis b and c among Thalassemia major patients in kerman, iran, and the Role of transfusion in infection acquisition. Govaresh, 2003. 8(3): p. 72-78.
63. Vahidi, A., A.G. Taheri, and Y. Nikian, Prevalence of Hepatitis C among Thalassemic patients referring to Kerman university of medical sciences hospital No. 1 in 1996. 2000.
64. Hassanshahi, G., et al., Post-transfusion-transmitted hepatitis C virus infection: a study on thalassemia and hemodialysis patients in southeastern Iran. Arch Virol, 2011. 156(7): p. 1111-5.
65. Arababadi, M.K., et al., No detected hepatitis B virus-DNA in thalassemic patients infected by hepatitis C virus in Kerman province of Iran. Pak J Biol Sci, 2008. 11(13): p. 1738-41.
66. Vahidi, A.A., et al., The frequency of β-thalasemia major complications in patients referred to Kerman Center for special diseases during 6 months. Journal of Kerman University of Medical Sciences, 2014. 18(4): p. 318-329.
67. Sayad, B., et al., Hepatitis B, hepatitis C, and human immunodeficiency virus infection in multi-transfused thalassemic patients, Kermanshah, Iran, 2015. Jundishapur Journal of Microbiology, 2017. 10(5).
68. Azarkar, Z., et al., Survey of HBV and HCV markers in haemodialysis and thalassemia, South Khorasan, Birjand 2007. Scientific Journal of Iranian Blood Transfusion Organization, 2009. 6(3): p. 233-237.
69. Kooti, S., et al., The prevalence of Hepatitis C virus antibodies among thalassemia patients referring to Shahid Beheshti Hospital, Abadan, Iran. Int J Enteric Pathog, 2017. 5(4): p. 111-114.
70. Company, F. and N. Rezaei, Study of prevalence of hepatitis C and its relationship with impaired glucose tolerance and diabetes mellitus in beta-thalassemic patients. Scientific Journal of Kurdistan University of Medical Sciences, 2008. 12(4): p. 45-52.
71. Kompani.
72. Boroujerdnia, G., Asarehzadegan, and Zandian, Seroprevalence Of Hepatitis B, Hepatitis C And Human Immunodeficiency Virus (Hiv) Among Thalassemia Patients Refer To Ahwaz Shapha Hospital (1999-2004). Jundishapur Scientific Medical Journal 2006. 5(2): p. 523-29.
73. Boroujerdnia, M.G., et al., Prevalence of hepatitis-C virus (HCV) among thalassemia patients in Khuzestan Province, Southwest Iran. Pak J Med Sci Q, 2009. 25(1): p. 113-7.
74. Sarkari, B., et al., High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med, 2012. 15(5): p. 271-4.
75. Mohammadi, S. and M. Khodabandehloo, Prevalence of Hepatitis C Virus Antibodies among Beta-Thalassemia Major Patients in Kurdistan Province, Iran. Arch Clin Infect Dis.
76. Vasmehjani, A.A., et al., The Prevalence of Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infections among β-thalassemia Major: A Multicenter Survey in Lorestan, West of Iran. Iranian Journal of Pediatric Hematology & Oncology, 2018. 8(2).
77. Samimi-Rad, K., et al., Prevalence of hepatitis C virus antibody and the risk factors for thalassemia and hemophilia patients in Markazi province. Journal of School of Public Health and Institute of Public Health Research, 2007. 5(3): p. 23-34.
78. Mahdaviani, F., S. Saremi, and M. Rafiee, Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004. The Scientific Journal of Iranian Blood Transfusion Organization, 2008. 4(5): p. 313-322.
79. Karami, H., et al., Assessment of demographic, clinical and laboratory status of patients with thalassemia major and intermedia referred to thalassemia research center in Sari, Iran, during 2007-2009. Pejouhandeh, 2010. 15(4).
80. Tamaddoni, A., I. Mohammadzadeh, and O. Ziaei, Seroprevalence of HCV antibody among patients with β-thalassemia major in Amirkola Thalassemia center, Iran. Iranian Journal of Allergy, Asthma and Immunology, 2007: p. 42-44.
81. Ghane, M., et al., Distribution of hepatitis C virus genotypes amongst the beta-thalassemia patients in North of Iran. Pakistan journal of biological sciences: PJBS, 2012. 15(15): p. 748-753.
82. Ameli, M., et al., Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Medical Journal, 2008. 29(11): p. 1611-1615.
83. Najafi, N., F. Babamahmoudi, and S. Azizi, A study on the Prevalence of chronic Hepatitis C in HCV-Ab positive patients referring to Gaemshahr Razi Hospital clinics in 1998. Journal of Mazandaran University of Medical Sciences, 2001. 11(30): p. 38-43.
84. Rafiei, A.R., et al., Risk factors for hepatitis C virus among high-risk populations (intravenous drug addicts and patients with Thalassemia, Hemophilia, Hemodialysis) in Mazandaran. Journal of Mazandaran University of Medical Sciences, 2011. 21(81): p. 32-42.
85. Alavian, S.M., et al., The Prevalence Of Hepatitis B And C Among Thalassemia Major Patients In Ghazvin Kowsar Medical Journal, 2003. 7(4): p. 319-326.
86. Bozorgi, S., et al., The prevalence and risk factors of hepatitis C virus infection among thalassemic patients of Qazvin (2005). The Journal Of Qazvin University Of Medical Sciences, 2008. 11(4): p. 54-59.
87. Sammak, H., H.A. Qomi, and M. Bitarafan, Prevalence of hepatitis B, C and HIV in patients with major β thalassaemia in Qom, 2007. Qom University of Medical Sciences Journal, 2010. 4(3).
88. Khosravi, S., et al., Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran. Archives of Clinical Infectious Diseases, 2018(In Press).
89. Yousefi, M., et al., The prevalence of hepatitis C virus infection in patients with thalassemia in Zabol city of Iran. International Journal of Infection, 2017. 4(1).
90. Bazi, A., et al., Characteristics of Seropositive Hepatitis B and C Thalassemia Major Patients in South-East of Iran. Biotechnology and Health Sciences, 2016. 3(2).
91. Sanei Moghaddam, E., S. Savadkoohi, and F. Rakhshani, Prevalence of hepatitis B and C in patients with major Beta-thalassaemia referred to Ali- Asghar hospital in Zahedan, 1381. The Scientific Journal of Iranian Blood Transfusion Organization, 2004. 1(1): p. 19-26.
92. Alavi, S., et al., Clinical outcomes of Torque teno virus-infected thalassemic patients with and without hepatitis C virus infection. The Korean journal of hematology, 2011. 46(2): p. 123-127.
93. Shamsian, B., et al., Blood transfusion status in beta major thalassemia patients in Mofid Children Hospital in Tehran. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2008. 4(4): p. 253-258.
94. Alvai, S., et al., Frequency of hepatitis C in thalassemic patients and its association with liver enzyme, MOfid Hospital, Iran, 2002. Research in Medicine, 2005. 29(3): p. 213-217.
95. Alavi, S., et al., Torque teno virus and hepatitis C virus co-infection in Iranian pediatric thalassemia patients. Turk J Haematol, 2012. 29(2): p. 156-61.
96. Amini, S., et al., Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health, 2005: p. 41-46.
97. Nakhaie and Talachian, Prevalence and characteristic of liver
involvement in thalassemia patients with HCV in Ali-Asghar
children hospital, Tehran, Iran (Farsi). J Iran Univ Med Sci, 2003. 2003;37:799–806.
98. Azar, K.A., et al., Evaluation Of Clinical Conditions Of Thalassemic Patients Having Referred To Adult Thalassemia Center, Tehran. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2011. 8(1): p. 32-41.
99. Mousavi, F. and B.M. Ale, A-IFN treatment of hepatitis C in thalassemic patients. Pejouhandeh, 2002. 7(1): p. 21-24.
100. Azarkeivan, A., et al., The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study. Transfusion, 2012. 52(8): p. 1814-8.
101. Bastani, M.N., et al., Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol, 2016. 161(7): p. 1899-906.
102. Azarkeivan, A., et al., Evaluation of Transfusion Reactions in Thalassemic Patients Referred to the Thehran Adult Thalssemia Clinic. Journal of Zanjan University of Medical Sciences, 2008. 16(62): p. 57-66.
103. Keshvari, M., et al., Seroepidemiology of human T‐cell lymphotropic virus among Iranian adult thalassemic patients. Transfusion Medicine, 2014. 24(4): p. 227-232.
104. Javadzadeh Shahshahani, H., et al., Study of the prevalence of hepatitis B, C and HIV infection in hemophilia and thalassemia population of Yazd. The Scientific Journal of Iranian Blood Transfusion Organization, 2006. 2(7): p. 315-322.
105. Tajbakhsh, R., Prevalence of hepatitis C and B virus infections among hemodialysis patients in Karaj, Iran. Saudi J Kidney Dis Transpl, 2015. 26(4): p. 792-6.
106. mamloki, M., Prevalence of hepatitis B and C in hemodialysis patients in Ardabil 2011. 2011.
107. Somi, M.H., et al., Hepatitis C virus genotypes in patients with end-stage renal disease in East Azerbaijan, Iran. Saudi J Kidney Dis Transpl, 2008. 19(3): p. 461-5.
108. Somi, M.H., et al., Risk factors of HCV seroconversion in hemodialysis patients in tabriz, iran. Hepat Mon, 2014. 14(6): p. e17417.
109. Kheradpezhouh, M., et al., Presence and significance of transfusion-transmitted virus infection in Iranian patients on maintenance hemodialysis. J Microbiol Immunol Infect, 2007. 40(2): p. 106-11.
110. Somi, M.H., et al., Hepatitis C virus infection in dialysis centers of Tabriz, Iran: a multicenter study. Archives of Clinical Infectious Diseases, 2007. 2(1).
111. MohammadHassan, K.A. and O. Mir-Davood, Evaluation of diagnostic value of Elisa method (EIA) and PCR in diagnosis of hepatitis C virus in hemodialysis patients. Hepatitis Monthly, 2006. 2006(1, Winter): p. 19-23.
112. Valizadeh, N., et al., Seroprevalence of hepatitis C, hepatitis B and HIV viruses in hemophiliacs born 1985-2010 in west Azarbaijan of Iran. Asian journal of transfusion science, 2013. 7(1): p. 55.
113. Alasvand, R., et al., Prevalence of hepatitis B and C in male prisoners in Iranian prisons. Int J Travel Med Glob Health, 2015. 3: p. 183-6.
114. Stoodeh Jahromi, R., f. Nejatollahi, and m.m. Hossaini, Prevalence of Anti-HCV antibody in haemodialysis patients referring to haemodialysis centers in Jahrom. Pars of Jahrom University of Medical Sciences, 2007. 5(3): p. 38-43.
115. Moini, M., et al., Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two methods; HCV core antigen and polymerase chain reaction. Hepatitis monthly, 2013. 13(6).
116. Mohsenzadeh, M., et al., Molecular evaluation of hepatitis G virus and hepatitis C virus in patients with chronic renal failure in Iran. Afr J Microbiol Res, 2012. 6(33): p. 6257-61.
117. Joukar, F., et al., Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients. Hepatitis monthly, 2011. 11(3): p. 178.
118. Dadgaran, S., Prevalence and risk factors of hepatitis C virus among hemodialysis patients. Journal of Guilan University of Medical Sciences, 2005. 14(55): p. 76-86.
119. Amiri, Z., A. Shakib, and M. Toorchi, Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J, 2005.
120. Mansour-Ghanaei, F., et al., Prevalence of hepatitis B and C infection in hemodialysis patients of Rasht (Center of Guilan Province, Northern Part of Iran). Hepat Mon, 2009. 9(1): p. 45-9.
121. Jabbari, A., S. Besharat, and B. Khodabakshi, Hepatitis C in hemodialysis centers of Golestan province, northeast of Iran (2005). Hepatitis monthly, 2008. 8(1): p. 61-65.
122. Mohammadalizadeh, A., M. Ranjbar, and A.S. Seyf, The Frequency Of Hepatitis C In Dialyse Patients In Hamadan Ekbatan Hospital. 7, 2002. 19(27-34).
123. Kheirabad, A.K., et al., Hepatitis C and G Virus infection prevalence among hemodialysis patients and associated risk factors in the Hormozgan province of southern Iran. Hepatitis monthly, 2016. 16(10).
124. Seyrafian, S., et al. Comparison and prevalence of hepatitis B and C infection and hepatitis B vaccination in hemodialysis patients and staffs in 13 hemodialysis centers in Isfahan (Iran). in Nephrology Dialysis Transplantation. 2006. OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND.
125. Kalantari, H., et al., Prevalence and risk factors of hepatitis B and C viruses among hemodialysis patients in Isfahan, Iran. Advanced biomedical research, 2014. 3.
126. Salehi, M., et al., Hepatitis G virus exposure in dialysis patients and blood donors in Isfahan-Iran. International journal of preventive medicine, 2014. 5(Suppl 3): p. S219.
127. Zahedi, M.J., et al., Seroprevalence of Hepatitis Viruses B, C, D and HIV Infection Among Hemodialysis Patients in Kerman Province, South-East Iran. Hepat Mon, 2012. 12(5): p. 339-43.
128. Arababadi, M.K., G. Hassanshahi, and H. Yousefi, HBV-DNA in hemodialysis patients infected by HCV. Saudi Journal of Kidney Diseases and Transplantation, 2009. 20(3): p. 398.
129. Sabour, B., et al., Prevalence and Risk Factors of Hepatitis C infection in hemodialysis Patients (Kermanshah , 1999 – 2000). J Kermanshah Univ Med Sci, 2003. 7(3): p. e81264.
130. Ziaee, M., R. Azizee, and M.H. Namaei, Prevalence of HCV infection in hemodialysis patients of South Khorasan in comparison With HBV, HDV, HTLV I/II, And HIV infection. Bangladesh Journal of Medical Science, 2014. 13(1): p. 36-39.
131. Beladi Mousavi, S.S., et al., Epidemiology of Hepatitis C Virus Infection in ESRD Patients in Khuzestan Province, Iran. Shiraz E-Med J, 2012. 13(3): p. 135-140.
132. Mousavi, S.S.B., F. Motemednia, and M.B. Mousavi, Epidemiology of hepatitis e virus infection in patients on chronic hemodialysis. Jundishapur journal of microbiology, 2014. 7(5).
133. Samarbaf-Zadeh, A.R., et al., Prevalence of hepatitis G virus among hemodialysis and kidney transplant patients in Khuzestan Province, Iran. Jundishapur journal of microbiology, 2015. 8(5).
134. Assarehzadegan, M.A., et al., Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl, 2009. 20(4): p. 681-4.
135. Mak, V.M., et al., A Study On The Prevalance Anti-Hepatitis C Virus Among The Hemodialysis Patients Referred To Sina Hospital Of Ahwaz. Jundishapur Scientific Medical Journal, 2001(29): p. 1-5.
136. Sohrabi, N., The Prevalence of Cytomegalovirus, Hepatitis B, Hepatitis C, and HIV Infections among Hemophilic Patients in Sanandaj in 2017. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2018. 12(02).
137. Samimi-Rad, K. and M. Hosseini, Hepatitis C virus infection and hcv genotypes of hemodialysis patients. Iranian Journal of Public Health, 2008: p. 146-152.
138. Roushan, M.R.H., et al., Epidemiological aspects of hepatitis B and C and human immunodeficiency viruses among hemodialysis patients in Mazandaran Province, Iran. Nephro-urology monthly, 2016. 8(3).
139. Darrudi, A., et al., Epidemiology of viral hepatitis among Hemodialysis patients in Mazandaran province, northern Iran, in First National Conference on Blood Transfusion Infection Management and Control (5th Mashhad Hepatitis Conference). 2018, Mashhad University of Medical Sciences, Baqiyatallah University of Medical Sciences, Iran, Hepatitis Iran.
140. Makhlough, A., M. Jamshidi, and M.R. Mahdavi, Hepatitis C prevalence studied by polymerase chain reaction and serological methods in haemodialysis patients in Mazandaran, Iran. Singapore Med J, 2008. 49(11): p. 921-3.
141. Taziki, O. and F. Espahbodi, Prevalence of hepatitis C virus infection in hemodialysis patients. Saudi journal of kidney diseases and transplantation, 2008. 19(3): p. 475.
142. Zamani, F., et al., Incidence of hepatitis C infection in patients on hemodialysis: a multicenter study of northern part of Iran. Saudi J Kidney Dis Transpl, 2010. 21(6): p. 1169-71.
143. Hamissi, J. and H. Hamissi, Occurrence of hepatitis B and C infection among hemodialyzed patients with chronic renal failure in Qazvin, Iran: A preliminary study. International Journal of Collaborative Research on Internal Medicine & Public Health, 2011. 3(1): p. 89.
144. Haghazali, S., et al., Occult HBV infection in hemodialysis patients in Qazvin. Razi Journal of Medical Sciences, 2011. 18(88): p. 8-15.
145. Bozorghi, S., et al., Assessment of prevalence and risk factors of hepatitis C virus infection in haemodialysis patients in Ghazvin. 2, 2006. 7(331-37).
146. Shad Afzar, M., Prevalence and Incidence of Hepatitis C in Hemodialysis Patients in Bo‑Ali Medical Center in Qazvin in 2003‑2004. Qazvin: Qazvin University of Medical Sciences and Health Services, 2007.
147. , et al., Study of prevalence and risk factors of hepatitis C in hemodialysis patients. Pajoohandeh, 2003. 8: p. 315–319.
148. Azadegan-Ghomi, H., et al. Prevalence of Hepatitis B, C, HIV in patients under dialysis in Ghom 1383. in The 3rd Iranian congress of virology. 2007.
149. Ghadir, M., et al., Effect of hepatitis C and B infections on anemia in hemodialysis patients. Journal of Medical Council of Islamic Republic of Iran, 2009. 27(1).
150. Babaei, M. and G. Saadedin. Comparison of prevalence of hepatitis C virus (HCV) infection among injection drug users (Idus) with other high risk groups: A case–control study of blood donors. in Tehran, Iran: 4th Iranian International Congress of Gastroenterology & Hepatology and 2nd Congress of From Bed to Bench in Gastroenterology & Liver Disease. 2004.
151. Dadmanesh, M., et al., Evaluation of prevalence and risk factors of hepatitis g virus infection among hemodialysis patients referred to Iranian army hospitals in tehran during 2012-2013. Hepat Mon, 2015. 15(1): p. e18322.
152. Ramezani, A., et al., Occult HCV Infection in Hemodialysis Patients with Elevated Liver Enzymes. Journal of Arak University of Medical Sciences, 2014. 16(11): p. 34-40.
153. Ataiee, N., Prevalence of hepatitis B and C infection among hemodialysis children and adolescents in Iran: a single center experience.
154. Aghakhani, A., et al., Significance of hepatitis B core antibody as the only marker of hepatitis B virus infection in high risk patients. Iranian Journal of Pathology, 2009. 4(2): p. 80-84.
155. Nemati, E., et al., Hepatitis C virus infection among patients on hemodialysis: a report from a single center in Iran. Saudi J Kidney Dis Transpl, 2009. 20(1): p. 147-53.
156. Eslamifar, A., et al., Hepatitis G virus exposure in dialysis patients. International urology and nephrology, 2007. 39(4): p. 1257-1263.
157. Toosi, M.N., et al., Risk factors and seroprevalence of hepatitis B and C infections among hemodialysis patients in Tehran. Iranian Journal of Pathology, 2007. 2(4): p. 181-6.
158. Alavian, S.M., et al., Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology, 2003. 8(5): p. 256-260.
159. Broumand, B., et al., Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in tehran: preliminary report from "the effect of dialysis unit isolation on the incidence of hepatitis C in dialysis patients" project. Saudi J Kidney Dis Transpl, 2002. 13(4): p. 467-72.
160. Samimi Rad, K., et al., Hepatitis C virus infection among multi-transfused patients and personnel in haemodialysis units in central Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2012.
161. Mobaien, A., et al., Hepatitis E virus seroprevalence in haemodialysis patients in Zanjan Province, Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2013.
162. Torabi, S., et al., Prevalence of hepatitis B, C and HIV in hemophiliac patients of East Azarbaijan in 2004. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2006. 2(7): p. 291-299.
163. Khamisipour, G. and R. Tahmasebi, Prevalence of HIV, HBV, HCV and syphilis infection in high risk groups of Bushehr Province, 1999. Iranian South Medical Journal, 2000. 1(3): p. 53-9.
164. Karimi, M., et al., Inherited coagulation disorders in southern Iran. Haemophilia, 2002. 8(6): p. 740-744.
165. Karimi, M. and A.A. Ghavanini, Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia (Budap), 2001. 31(3): p. 251-5.
166. Mansour-Ghanaei, F., et al., Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Medical Science Monitor, 2002. 8(12): p. CR797-CR800.
167. Esfahani, H. and H. Bazmamoun, The prevalence of blood-borne viral infection (HBV, HCV, HIV) among hemophilia patients in Hamedan province of Iran. Iranian Journal of Blood and Cancer, 2014. 6(4): p. 209-211.
168. Alizadeh, M., Frequencies of hepatitis B and C infections in hemophiliacs. Pejouhesh dar Pezeshki (Research in Medicine), 2006. 30(2): p. 119-123.
169. Naini, M.M., et al., Analysis of the related factors in hepatitis C virus infection among hemophilic patients in Isfahan, Iran. Hepat Mon, 2007. 7(2): p. 59-62.
170. Yazdani, M.R., et al., Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. International journal of preventive medicine, 2012. 3(Suppl1): p. S89.
171. Zahedi, M.J. and M.S. Darvish, Frequency of Hepatitis B and C infection among Hemophiliac patients in Kerman. Journal of Kerman University of Medical Sciences, 2004.
172. Ziaee, M., et al., Prevalence Of HCV Infection And Related Viremia In Hemophilic Patients Registered In Khorasan Hemophilia Society. The Horizon of Medical Sciences, 2005. 11(3): p. 54-60.
173. Ziaee, M., M.H. Namaei, and G. Azarkar, The prevalence of HTLV-1 and its co-infection with HCV, HBV and HIV in hemophilic patients. Pakistan journal of medical sciences, 2015. 31(5): p. 1246.
174. Ziaee, M., et al., Evaluation of HGV viremia prevalence and its co-infection with HBV, HCV, HIV and HTLV-1 in hemophilic patients of Southern Khorassan, Iran. Hepat Mon, 2007. 7(1): p. 11-4.
175. Ghafourian-Boroujerdnia, M., M.A. Assarehzadegan, and K. Zandian, Hepatitis B and C infections and different genotypes of HCV among sickle cell anemia patients in Ahvaz, South-Western Iran. Jundishapur Journal of Microbiology, 2013. 6(5).
176. Assarehzadegan, M.A., M.G. Boroujerdnia, and K. Zandian, Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran. Iranian Red Crescent Medical Journal, 2012. 14(8): p. 470.
177. Samimi-Rad, K. and B. Shahbaz, Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia, 2007. 13(2): p. 156-63.
178. Mahdaviani, F., S. Saremi, and M. Rafiei, Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2008. 4(5): p. 313-322.
179. Sharifi-Mood, B., et al., Viral infection among patients with hemophilia in the Southeast of Iran. J Med Sci, 2006. 6(2): p. 225-8.
180. Sharifi-Mood, B., et al., Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi medical journal, 2007. 28(10): p. 1516-1519.
181. Lak, M., F. Peyvandi, and P. Mannucci, Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British journal of haematology, 2000. 111(4): p. 1236-1239.
182. Alavian, S., A. Ardeshir, and B. Hajarizadeh, Seroprevalence of anti-HCV among Iranian hemophilia patients. TRANSFUSION TODAY-GRONINGEN-, 2001: p. 4-4.
183. Abdollahi, A., et al., Seroprevalence of human immunodificiency virus (HIV) and hepatitis C infection in hemophilic patients in Iran. Iranian Journal of Pathology, 2008. 3(3): p. 119-124.
184. Mousavian, S., et al., Seroprevalence of hepatitis C in hemophilia patients refering to Iran Hemophilia Society Center in Tehran. Govaresh, 2011. 16(3): p. 169-174.
185. Javadzadeh, S.H., et al., Study of the prevalence of Hepatitis B, C and HIV infection in Hemophilia and Thalassemia population of Yazd. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon), 2006. 2(7): p. 315-322.
186. Mobini, G., et al., Prevalence of anti-HCV antibody and related risk factors among bleeding disorder patients in Yazd province of Iran. Journal of Shahrekord Uuniversity of Medical Sciences, 2010. 12(3): p. 36-42.
2. who, World Health Organization. 2018.
3. Mohd Hanafiah, K., et al., Global epidemiology of hepatitis C virus infection: new estimates of age‐specific antibody to HCV seroprevalence. Hepatology, 2013. 57(4): p. 1333-1342.
4. Jamali, R., Epidemiologic studies on viral hepatitis: a short review. Thrita, 2014. 3(1).
5. WHO, WHO. Global Hepatitis Report. 2017.
6. WHO, The epidemiology of hepatitis C virus in the World Health
Organization Eastern Mediterranean Region: Implications for strategic
action. Eastern Mediterranean Hepatitis C Virus Epidemiology
Synthesis Project. 2017.
7. Eissa, S., et al., National Cancer Institute experience in healthy Egyptian blood donors as regards blood group frequencies and seroprevalence of hepatitis b virus, hepatitis C Virus & HIV: 10 year evaluation. J Egypt Natl Canc Inst, 2007. 19(1): p. 71-6.
8. Chakrabarti, S., et al., Prevalence of anti HCV, HBsAg and HIV antibodies in high risk recipients of blood and blood products. Indian journal of public health, 2006. 50(1): p. 43-44.
9. Mirmomen, S., et al., Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infecions in patients with beta-thalassemia in Iran: a multicenter study. Arch Iran Med, 2006. 9(4): p. 319-23.
10. Kabir, A., S.-M. Alavian, and H. Keyvani, Distribution of hepatitis C virus genotypes in patients infected by different sources and its correlation with clinical and virological parameters: a preliminary study. Comparative Hepatology, 2006. 5(1): p. 4.
11. Remis, R., A study to characterize the epidemiology of hepatitis C infection in Canada: final report. Public Health Agency of Canada, 2002.
12. Makhloogh, A., et al., Hepatitis C prevalence in hemodialysis patients in Mazandaran, Iran: A survey by polymerase chain reaction and serological methods. Res J Biol Sci, 2008. 3(4): p. 265-268.
13. Alavian, S.-M., P. Adibi, and M.R. ZALI, Hepatitis C virus in Iran: Epidemiology of an emerging infection. 2005.
14. Khan, S., et al., Molecular epidemiology of HCV among health care workers of Khyber Pakhtunkhwa. Virology Journal, 2011. 8(1): p. 105.
15. L, F., et al., National surveillance of dialysis-associated diseases in the United States. 18, 2002. 1: p. 52-61.
16. Griveas, I., et al., Acute hepatitis C in patients receiving hemodialysis. Renal failure, 2007. 29(6): p. 731-736.
17. Mahmud, S., V. Akbarzadeh, and L.J. Abu-Raddad, The epidemiology of hepatitis C virus in Iran: systematic review and meta-analyses. Scientific reports, 2018. 8(1): p. 150.
18. WHO, Global Hepatitis Report. 2017.
19. Behzadifar, M., et al., Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of virus eradication, 2019. 5(2): p. 116.
20. Moher, D., et al., Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev.[Internet]. 2015; 4: 1.
21. Downes, M.J., et al., Development of a critical appraisal tool to assess the quality of cross-sectional studies (AXIS). BMJ open, 2016. 6(12): p. e011458.
22. Salehi-Vaziri, M., et al., Hepatitis B virus infection in the general population of Iran: an updated systematic review and meta-analysis. Hepatitis monthly, 2016. 16(4).
23. Schafer, J.L., Analysis of incomplete multivariate data. 1997: Chapman and Hall/CRC.
24. Najimi Varzaneh, a. and m. Gholami Fesharaki, Prevalence of road traffic accidents in iran: A systematic review, gis and meta-analysis. Iranian red crescent medical journal (ircmj), 2018. 20(10): p. -.
25. Brown, L.D., T.T. Cai, and A. DasGupta, Interval estimation for a binomial proportion. Statistical science, 2001: p. 101-117.
26. Alavian, S.M., et al., Hepatitis C infection in the general population of Iran: a systematic review. Hepatitis Monthly, 2009. 9(3).
27. Mirminachi, B., et al., Update on the prevalence of hepatitis C virus infection among Iranian general population: a systematic review and meta-analysis. Hepatitis Monthly, 2017. 17(2).
28. Shamshirian, A., et al., Seroprevalence and geographical distribution of hepatitis C virus in Iranian patients with thalassemia: a systematic review and meta-analysis. Journal of Laboratory Medicine, 2019. 43(2): p. 45-55.
29. Behzadifar, M., H.A. Gorji, and N.L. Bragazzi, The prevalence of hepatitis C virus infection in thalassemia patients in Iran from 2000 to 2017: a systematic review and meta-analysis. Archives of Virology, 2018. 163(5): p. 1131-1140.
30. Ashkani-Esfahani, S., S.M. Alavian, and M. Salehi-Marzijarani, Prevalence of hepatitis C virus infection among hemodialysis patients in the Middle-East: A systematic review and meta-analysis. World journal of gastroenterology, 2017. 23(1): p. 151.
31. ALAVIAN, S.M., et al., Hepatitis C infection in hemodialysis patients in Iran: a systematic review. Hemodialysis International, 2010. 14(3): p. 253-262.
32. Ghorbani, N.R., et al., Prevalence of hepatitis C infection in Iranian hemodialysis patients: An updated systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences, 2017. 22: p. 123-123.
33. G, s., et al., Prevalence of hepatitis C antibodies in hemophilic patients.
34. Ebrahimpour, S., M. YAGHOUBI, and V. Gharamaleki, Seropidemiological studies of hepatitis B and C in haemophiliacs in northwestern Iran. 1997.
35. L., M., Prevalence of hepatitis B , C and hiv in hemophilia patients. Seminar on Hereditary Hemorrhagic Diseases., 2004.
36. Khazaei, S., et al., The Epidemiology and Trend of Hepatitis C Infection in Hamadan Province: West of Iran, 2011-2016. VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, 2018. 24(3): p. 65-69.
37. Kashanchi Langarodi, M. and H. Abdolrahim Poorheravi, Prevalence of HCV among thalassemia patients in Shahid Bahonar Hospital, Karaj. The Scientific Journal of Iranian Blood Transfusion Organization, 2011. 8(2): p. 137-142.
38. Manuchehr, B., et al., Investigating the Infection with Viral Hepatitis C in Repeated Blood Transfusions in Ardabil Province, 2000. Ardabil Scientific Research Journal, 2003. 2(6).
39. Mashayekhi, Prevalence of blood transfusion induced hepatitis among patients with thalassemia in Tabriz. Hepatology International 2011. 5(1): p. 225.
40. Torabi, S., et al., Prevalence of hepatitis B and C in thalassemic patients of East Azarbaijan in 2003. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2005. 2(4): p. 115-122.
41. Valizadeh, N., et al., Seroprevalence of Hepatitis B, Hepatitis C and Human Immunodeficiency Viruses among Thalassemia Patients in West North of Iran. Iranian journal of pediatric hematology and oncology, 2015. 5(3): p. 145-148.
42. Reisi, N. and P. Raeisi, Molecular evaluation of HCV infection by RT-PCR test in major beta thalassemia patients, Hajar Hospital of Shahrekord. khoon, 2011.
43. Basirat nia, M., et al., Hepatitis C prevalence in Thalassemic children in Shahrekord. Journal of Shahrekord Uuniversity of Medical Sciences, 2000. 1(4): p. 13-18.
44. Karimi, M. and A.A. Ghavanini, Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. J Paediatr Child Health, 2001. 37(6): p. 564-6.
45. Hedayat, et al., Prevalence and Cause of Hepatitis B and C in Thalassemia and Hemophilia Patients in Fasa City 2003-2004. 6th GCC Medical Students Conference; 2009., 2009.
46. Ansari, H., H. Kamani, and A. Arbabi-Sarjo, Prevalence of hepatitis C and related factors among beta-thalassemia major patients in Southern Iran in 2005-2006. J Med Sci, 2007. 7(6): p. 997-1002.
47. Karimi, M. and A.A. Ghavanini, Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia, 2001. 31(3): p. 251-255.
48. Kashef, S., et al., Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. Int J Lab Hematol, 2008. 30(1): p. 11-6.
49. Yaghobi, R., et al., A study on the serologic and molecular prevalence of hepatitis G virus (HGV) and hepatitis C virus (HCV) infections in patients with thalassemia in Larestan of Iran. African Journal of Microbiology Research, 2012. 6(29): p. 5866-5870.
50. Akbari, A., et al., Hepatitis C Virus Antibody Positive Cases in Multitransfused Thalassemic Patients in South of Iran. Hepat Mon. 7(2): p. 63-66.
51. Jafroodi, M., et al., Trend in Prevalence of Hepatitis C Virus Infection among beta-thalassemia Major Patients: 10 Years of Experience in Iran. Int J Prev Med, 2015. 6: p. 89.
52. Ansar, M.M. and A. Kooloobandi, Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. J Viral Hepat, 2002. 9(5): p. 390-2.
53. Mansour-Ghanaei, F., et al., prevalence of Transfusion Transmitted Infections Among Patients with Major Thalassemia in Guilan, the North Province of Iran:# 1937. Transfusion, 2009. 49(10): p. 2258.
54. Kh. Oshvandi, P.D., B.S. M. Bakhshi, and B.S. F. Pourazizi, The Investigation of Blood Transfusion’s Complications of Thalassemic Patients in Educational Hospitals of Hamadan Medical Science University. Avicenna Journal of Nursing and Midfery Care, 2009. 17(12): p. 53-63.
55. Eghbalian, F. and A. Monsef, Study of Prevalence of Posttransfusion Infections in Hamadan Thalassemic Children. Avicenna Journal of Clinical Medicine, 2000. 7(3): p. 0-0.
56. Aminianfar, M., F. Khani, and I. Ghasemzadeh, Evaluation of hepatitis C, hepatitis B, and HIV virus Serology pandemic in thalassemia patients of Shahid Mohammadi Hospital of Bandar Abbas, Iran. Electronic physician, 2017. 9(3): p. 4014.
57. Ataei, B., et al., Prevalence of anti HCV infection in patients with Beta-thalassemia in isfahan-iran. Int J Prev Med, 2012. 3(Suppl 1): p. S118-23.
58. Kalantari, H., et al., Prevalence of hepatitis C virus, hepatitis B virus, human immunodeficiency virus and related risk factors among hemophilia and thalassemia patients In Iran. Archives of Clinical Infectious Diseases, 2011. 6(2): p. 82-84.
59. Kassaian, N., et al., Hepatitis C in Patients with Multi Blood Transfusion. Journal of Isfahan Medical School, 2011. 28.
60. Hariri, M., et al. Prevalence of hepatitis B, C and HIV markers in thalassemic and haemophilic patients in Isfahan, Iran, 2004. in Vox Sanguinis. 2008. WILEY-BLACKWELL COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA.
61. Naghavi, N., et al., Hepatitis C virus infection among haemophilia and thalassemia patients in Isfahan in 2005. Iranian Journal Of Infectious Diseases And Tropical Medicine, 2007. 11(35): p. 33-39.
62. Zahedi, M., et al., The prevalence of heptitis b and c among Thalassemia major patients in kerman, iran, and the Role of transfusion in infection acquisition. Govaresh, 2003. 8(3): p. 72-78.
63. Vahidi, A., A.G. Taheri, and Y. Nikian, Prevalence of Hepatitis C among Thalassemic patients referring to Kerman university of medical sciences hospital No. 1 in 1996. 2000.
64. Hassanshahi, G., et al., Post-transfusion-transmitted hepatitis C virus infection: a study on thalassemia and hemodialysis patients in southeastern Iran. Arch Virol, 2011. 156(7): p. 1111-5.
65. Arababadi, M.K., et al., No detected hepatitis B virus-DNA in thalassemic patients infected by hepatitis C virus in Kerman province of Iran. Pak J Biol Sci, 2008. 11(13): p. 1738-41.
66. Vahidi, A.A., et al., The frequency of β-thalasemia major complications in patients referred to Kerman Center for special diseases during 6 months. Journal of Kerman University of Medical Sciences, 2014. 18(4): p. 318-329.
67. Sayad, B., et al., Hepatitis B, hepatitis C, and human immunodeficiency virus infection in multi-transfused thalassemic patients, Kermanshah, Iran, 2015. Jundishapur Journal of Microbiology, 2017. 10(5).
68. Azarkar, Z., et al., Survey of HBV and HCV markers in haemodialysis and thalassemia, South Khorasan, Birjand 2007. Scientific Journal of Iranian Blood Transfusion Organization, 2009. 6(3): p. 233-237.
69. Kooti, S., et al., The prevalence of Hepatitis C virus antibodies among thalassemia patients referring to Shahid Beheshti Hospital, Abadan, Iran. Int J Enteric Pathog, 2017. 5(4): p. 111-114.
70. Company, F. and N. Rezaei, Study of prevalence of hepatitis C and its relationship with impaired glucose tolerance and diabetes mellitus in beta-thalassemic patients. Scientific Journal of Kurdistan University of Medical Sciences, 2008. 12(4): p. 45-52.
71. Kompani.
72. Boroujerdnia, G., Asarehzadegan, and Zandian, Seroprevalence Of Hepatitis B, Hepatitis C And Human Immunodeficiency Virus (Hiv) Among Thalassemia Patients Refer To Ahwaz Shapha Hospital (1999-2004). Jundishapur Scientific Medical Journal 2006. 5(2): p. 523-29.
73. Boroujerdnia, M.G., et al., Prevalence of hepatitis-C virus (HCV) among thalassemia patients in Khuzestan Province, Southwest Iran. Pak J Med Sci Q, 2009. 25(1): p. 113-7.
74. Sarkari, B., et al., High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, Southwest Iran. Arch Iran Med, 2012. 15(5): p. 271-4.
75. Mohammadi, S. and M. Khodabandehloo, Prevalence of Hepatitis C Virus Antibodies among Beta-Thalassemia Major Patients in Kurdistan Province, Iran. Arch Clin Infect Dis.
76. Vasmehjani, A.A., et al., The Prevalence of Hepatitis B, Hepatitis C, and Human Immunodeficiency Virus Infections among β-thalassemia Major: A Multicenter Survey in Lorestan, West of Iran. Iranian Journal of Pediatric Hematology & Oncology, 2018. 8(2).
77. Samimi-Rad, K., et al., Prevalence of hepatitis C virus antibody and the risk factors for thalassemia and hemophilia patients in Markazi province. Journal of School of Public Health and Institute of Public Health Research, 2007. 5(3): p. 23-34.
78. Mahdaviani, F., S. Saremi, and M. Rafiee, Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004. The Scientific Journal of Iranian Blood Transfusion Organization, 2008. 4(5): p. 313-322.
79. Karami, H., et al., Assessment of demographic, clinical and laboratory status of patients with thalassemia major and intermedia referred to thalassemia research center in Sari, Iran, during 2007-2009. Pejouhandeh, 2010. 15(4).
80. Tamaddoni, A., I. Mohammadzadeh, and O. Ziaei, Seroprevalence of HCV antibody among patients with β-thalassemia major in Amirkola Thalassemia center, Iran. Iranian Journal of Allergy, Asthma and Immunology, 2007: p. 42-44.
81. Ghane, M., et al., Distribution of hepatitis C virus genotypes amongst the beta-thalassemia patients in North of Iran. Pakistan journal of biological sciences: PJBS, 2012. 15(15): p. 748-753.
82. Ameli, M., et al., Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. Saudi Medical Journal, 2008. 29(11): p. 1611-1615.
83. Najafi, N., F. Babamahmoudi, and S. Azizi, A study on the Prevalence of chronic Hepatitis C in HCV-Ab positive patients referring to Gaemshahr Razi Hospital clinics in 1998. Journal of Mazandaran University of Medical Sciences, 2001. 11(30): p. 38-43.
84. Rafiei, A.R., et al., Risk factors for hepatitis C virus among high-risk populations (intravenous drug addicts and patients with Thalassemia, Hemophilia, Hemodialysis) in Mazandaran. Journal of Mazandaran University of Medical Sciences, 2011. 21(81): p. 32-42.
85. Alavian, S.M., et al., The Prevalence Of Hepatitis B And C Among Thalassemia Major Patients In Ghazvin Kowsar Medical Journal, 2003. 7(4): p. 319-326.
86. Bozorgi, S., et al., The prevalence and risk factors of hepatitis C virus infection among thalassemic patients of Qazvin (2005). The Journal Of Qazvin University Of Medical Sciences, 2008. 11(4): p. 54-59.
87. Sammak, H., H.A. Qomi, and M. Bitarafan, Prevalence of hepatitis B, C and HIV in patients with major β thalassaemia in Qom, 2007. Qom University of Medical Sciences Journal, 2010. 4(3).
88. Khosravi, S., et al., Hepatitis B and Hepatitis C in Patients with Inherited Disorders of Hemoglobin in Sistan and Baluchistan Province, Iran. Archives of Clinical Infectious Diseases, 2018(In Press).
89. Yousefi, M., et al., The prevalence of hepatitis C virus infection in patients with thalassemia in Zabol city of Iran. International Journal of Infection, 2017. 4(1).
90. Bazi, A., et al., Characteristics of Seropositive Hepatitis B and C Thalassemia Major Patients in South-East of Iran. Biotechnology and Health Sciences, 2016. 3(2).
91. Sanei Moghaddam, E., S. Savadkoohi, and F. Rakhshani, Prevalence of hepatitis B and C in patients with major Beta-thalassaemia referred to Ali- Asghar hospital in Zahedan, 1381. The Scientific Journal of Iranian Blood Transfusion Organization, 2004. 1(1): p. 19-26.
92. Alavi, S., et al., Clinical outcomes of Torque teno virus-infected thalassemic patients with and without hepatitis C virus infection. The Korean journal of hematology, 2011. 46(2): p. 123-127.
93. Shamsian, B., et al., Blood transfusion status in beta major thalassemia patients in Mofid Children Hospital in Tehran. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2008. 4(4): p. 253-258.
94. Alvai, S., et al., Frequency of hepatitis C in thalassemic patients and its association with liver enzyme, MOfid Hospital, Iran, 2002. Research in Medicine, 2005. 29(3): p. 213-217.
95. Alavi, S., et al., Torque teno virus and hepatitis C virus co-infection in Iranian pediatric thalassemia patients. Turk J Haematol, 2012. 29(2): p. 156-61.
96. Amini, S., et al., Prevalence of hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health, 2005: p. 41-46.
97. Nakhaie and Talachian, Prevalence and characteristic of liver
involvement in thalassemia patients with HCV in Ali-Asghar
children hospital, Tehran, Iran (Farsi). J Iran Univ Med Sci, 2003. 2003;37:799–806.
98. Azar, K.A., et al., Evaluation Of Clinical Conditions Of Thalassemic Patients Having Referred To Adult Thalassemia Center, Tehran. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2011. 8(1): p. 32-41.
99. Mousavi, F. and B.M. Ale, A-IFN treatment of hepatitis C in thalassemic patients. Pejouhandeh, 2002. 7(1): p. 21-24.
100. Azarkeivan, A., et al., The incidence of hepatitis C in patients with thalassemia after screening in blood transfusion centers: a fourteen-year study. Transfusion, 2012. 52(8): p. 1814-8.
101. Bastani, M.N., et al., Prevalence of occult hepatitis C virus infection in Iranian patients with beta thalassemia major. Arch Virol, 2016. 161(7): p. 1899-906.
102. Azarkeivan, A., et al., Evaluation of Transfusion Reactions in Thalassemic Patients Referred to the Thehran Adult Thalssemia Clinic. Journal of Zanjan University of Medical Sciences, 2008. 16(62): p. 57-66.
103. Keshvari, M., et al., Seroepidemiology of human T‐cell lymphotropic virus among Iranian adult thalassemic patients. Transfusion Medicine, 2014. 24(4): p. 227-232.
104. Javadzadeh Shahshahani, H., et al., Study of the prevalence of hepatitis B, C and HIV infection in hemophilia and thalassemia population of Yazd. The Scientific Journal of Iranian Blood Transfusion Organization, 2006. 2(7): p. 315-322.
105. Tajbakhsh, R., Prevalence of hepatitis C and B virus infections among hemodialysis patients in Karaj, Iran. Saudi J Kidney Dis Transpl, 2015. 26(4): p. 792-6.
106. mamloki, M., Prevalence of hepatitis B and C in hemodialysis patients in Ardabil 2011. 2011.
107. Somi, M.H., et al., Hepatitis C virus genotypes in patients with end-stage renal disease in East Azerbaijan, Iran. Saudi J Kidney Dis Transpl, 2008. 19(3): p. 461-5.
108. Somi, M.H., et al., Risk factors of HCV seroconversion in hemodialysis patients in tabriz, iran. Hepat Mon, 2014. 14(6): p. e17417.
109. Kheradpezhouh, M., et al., Presence and significance of transfusion-transmitted virus infection in Iranian patients on maintenance hemodialysis. J Microbiol Immunol Infect, 2007. 40(2): p. 106-11.
110. Somi, M.H., et al., Hepatitis C virus infection in dialysis centers of Tabriz, Iran: a multicenter study. Archives of Clinical Infectious Diseases, 2007. 2(1).
111. MohammadHassan, K.A. and O. Mir-Davood, Evaluation of diagnostic value of Elisa method (EIA) and PCR in diagnosis of hepatitis C virus in hemodialysis patients. Hepatitis Monthly, 2006. 2006(1, Winter): p. 19-23.
112. Valizadeh, N., et al., Seroprevalence of hepatitis C, hepatitis B and HIV viruses in hemophiliacs born 1985-2010 in west Azarbaijan of Iran. Asian journal of transfusion science, 2013. 7(1): p. 55.
113. Alasvand, R., et al., Prevalence of hepatitis B and C in male prisoners in Iranian prisons. Int J Travel Med Glob Health, 2015. 3: p. 183-6.
114. Stoodeh Jahromi, R., f. Nejatollahi, and m.m. Hossaini, Prevalence of Anti-HCV antibody in haemodialysis patients referring to haemodialysis centers in Jahrom. Pars of Jahrom University of Medical Sciences, 2007. 5(3): p. 38-43.
115. Moini, M., et al., Hepatitis C virus (HCV) infection rate among seronegative hemodialysis patients screened by two methods; HCV core antigen and polymerase chain reaction. Hepatitis monthly, 2013. 13(6).
116. Mohsenzadeh, M., et al., Molecular evaluation of hepatitis G virus and hepatitis C virus in patients with chronic renal failure in Iran. Afr J Microbiol Res, 2012. 6(33): p. 6257-61.
117. Joukar, F., et al., Hepatitis C and hepatitis B seroprevalence and associated risk factors in hemodialysis patients in Guilan province, north of Iran: HCV and HBV seroprevalence in hemodialysis patients. Hepatitis monthly, 2011. 11(3): p. 178.
118. Dadgaran, S., Prevalence and risk factors of hepatitis C virus among hemodialysis patients. Journal of Guilan University of Medical Sciences, 2005. 14(55): p. 76-86.
119. Amiri, Z., A. Shakib, and M. Toorchi, Seroprevalence of hepatitis C and risk factors in haemodialysis patients in Guilan, Islamic Republic of Iran. East Mediterr Health J, 2005.
120. Mansour-Ghanaei, F., et al., Prevalence of hepatitis B and C infection in hemodialysis patients of Rasht (Center of Guilan Province, Northern Part of Iran). Hepat Mon, 2009. 9(1): p. 45-9.
121. Jabbari, A., S. Besharat, and B. Khodabakshi, Hepatitis C in hemodialysis centers of Golestan province, northeast of Iran (2005). Hepatitis monthly, 2008. 8(1): p. 61-65.
122. Mohammadalizadeh, A., M. Ranjbar, and A.S. Seyf, The Frequency Of Hepatitis C In Dialyse Patients In Hamadan Ekbatan Hospital. 7, 2002. 19(27-34).
123. Kheirabad, A.K., et al., Hepatitis C and G Virus infection prevalence among hemodialysis patients and associated risk factors in the Hormozgan province of southern Iran. Hepatitis monthly, 2016. 16(10).
124. Seyrafian, S., et al. Comparison and prevalence of hepatitis B and C infection and hepatitis B vaccination in hemodialysis patients and staffs in 13 hemodialysis centers in Isfahan (Iran). in Nephrology Dialysis Transplantation. 2006. OXFORD UNIV PRESS GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND.
125. Kalantari, H., et al., Prevalence and risk factors of hepatitis B and C viruses among hemodialysis patients in Isfahan, Iran. Advanced biomedical research, 2014. 3.
126. Salehi, M., et al., Hepatitis G virus exposure in dialysis patients and blood donors in Isfahan-Iran. International journal of preventive medicine, 2014. 5(Suppl 3): p. S219.
127. Zahedi, M.J., et al., Seroprevalence of Hepatitis Viruses B, C, D and HIV Infection Among Hemodialysis Patients in Kerman Province, South-East Iran. Hepat Mon, 2012. 12(5): p. 339-43.
128. Arababadi, M.K., G. Hassanshahi, and H. Yousefi, HBV-DNA in hemodialysis patients infected by HCV. Saudi Journal of Kidney Diseases and Transplantation, 2009. 20(3): p. 398.
129. Sabour, B., et al., Prevalence and Risk Factors of Hepatitis C infection in hemodialysis Patients (Kermanshah , 1999 – 2000). J Kermanshah Univ Med Sci, 2003. 7(3): p. e81264.
130. Ziaee, M., R. Azizee, and M.H. Namaei, Prevalence of HCV infection in hemodialysis patients of South Khorasan in comparison With HBV, HDV, HTLV I/II, And HIV infection. Bangladesh Journal of Medical Science, 2014. 13(1): p. 36-39.
131. Beladi Mousavi, S.S., et al., Epidemiology of Hepatitis C Virus Infection in ESRD Patients in Khuzestan Province, Iran. Shiraz E-Med J, 2012. 13(3): p. 135-140.
132. Mousavi, S.S.B., F. Motemednia, and M.B. Mousavi, Epidemiology of hepatitis e virus infection in patients on chronic hemodialysis. Jundishapur journal of microbiology, 2014. 7(5).
133. Samarbaf-Zadeh, A.R., et al., Prevalence of hepatitis G virus among hemodialysis and kidney transplant patients in Khuzestan Province, Iran. Jundishapur journal of microbiology, 2015. 8(5).
134. Assarehzadegan, M.A., et al., Prevalence of hepatitis C and B infection and HC V genotypes among hemodialysis patients in Khuzestan province, southwest Iran. Saudi J Kidney Dis Transpl, 2009. 20(4): p. 681-4.
135. Mak, V.M., et al., A Study On The Prevalance Anti-Hepatitis C Virus Among The Hemodialysis Patients Referred To Sina Hospital Of Ahwaz. Jundishapur Scientific Medical Journal, 2001(29): p. 1-5.
136. Sohrabi, N., The Prevalence of Cytomegalovirus, Hepatitis B, Hepatitis C, and HIV Infections among Hemophilic Patients in Sanandaj in 2017. Asian Journal of Pharmaceutics (AJP): Free full text articles from Asian J Pharm, 2018. 12(02).
137. Samimi-Rad, K. and M. Hosseini, Hepatitis C virus infection and hcv genotypes of hemodialysis patients. Iranian Journal of Public Health, 2008: p. 146-152.
138. Roushan, M.R.H., et al., Epidemiological aspects of hepatitis B and C and human immunodeficiency viruses among hemodialysis patients in Mazandaran Province, Iran. Nephro-urology monthly, 2016. 8(3).
139. Darrudi, A., et al., Epidemiology of viral hepatitis among Hemodialysis patients in Mazandaran province, northern Iran, in First National Conference on Blood Transfusion Infection Management and Control (5th Mashhad Hepatitis Conference). 2018, Mashhad University of Medical Sciences, Baqiyatallah University of Medical Sciences, Iran, Hepatitis Iran.
140. Makhlough, A., M. Jamshidi, and M.R. Mahdavi, Hepatitis C prevalence studied by polymerase chain reaction and serological methods in haemodialysis patients in Mazandaran, Iran. Singapore Med J, 2008. 49(11): p. 921-3.
141. Taziki, O. and F. Espahbodi, Prevalence of hepatitis C virus infection in hemodialysis patients. Saudi journal of kidney diseases and transplantation, 2008. 19(3): p. 475.
142. Zamani, F., et al., Incidence of hepatitis C infection in patients on hemodialysis: a multicenter study of northern part of Iran. Saudi J Kidney Dis Transpl, 2010. 21(6): p. 1169-71.
143. Hamissi, J. and H. Hamissi, Occurrence of hepatitis B and C infection among hemodialyzed patients with chronic renal failure in Qazvin, Iran: A preliminary study. International Journal of Collaborative Research on Internal Medicine & Public Health, 2011. 3(1): p. 89.
144. Haghazali, S., et al., Occult HBV infection in hemodialysis patients in Qazvin. Razi Journal of Medical Sciences, 2011. 18(88): p. 8-15.
145. Bozorghi, S., et al., Assessment of prevalence and risk factors of hepatitis C virus infection in haemodialysis patients in Ghazvin. 2, 2006. 7(331-37).
146. Shad Afzar, M., Prevalence and Incidence of Hepatitis C in Hemodialysis Patients in Bo‑Ali Medical Center in Qazvin in 2003‑2004. Qazvin: Qazvin University of Medical Sciences and Health Services, 2007.
147. , et al., Study of prevalence and risk factors of hepatitis C in hemodialysis patients. Pajoohandeh, 2003. 8: p. 315–319.
148. Azadegan-Ghomi, H., et al. Prevalence of Hepatitis B, C, HIV in patients under dialysis in Ghom 1383. in The 3rd Iranian congress of virology. 2007.
149. Ghadir, M., et al., Effect of hepatitis C and B infections on anemia in hemodialysis patients. Journal of Medical Council of Islamic Republic of Iran, 2009. 27(1).
150. Babaei, M. and G. Saadedin. Comparison of prevalence of hepatitis C virus (HCV) infection among injection drug users (Idus) with other high risk groups: A case–control study of blood donors. in Tehran, Iran: 4th Iranian International Congress of Gastroenterology & Hepatology and 2nd Congress of From Bed to Bench in Gastroenterology & Liver Disease. 2004.
151. Dadmanesh, M., et al., Evaluation of prevalence and risk factors of hepatitis g virus infection among hemodialysis patients referred to Iranian army hospitals in tehran during 2012-2013. Hepat Mon, 2015. 15(1): p. e18322.
152. Ramezani, A., et al., Occult HCV Infection in Hemodialysis Patients with Elevated Liver Enzymes. Journal of Arak University of Medical Sciences, 2014. 16(11): p. 34-40.
153. Ataiee, N., Prevalence of hepatitis B and C infection among hemodialysis children and adolescents in Iran: a single center experience.
154. Aghakhani, A., et al., Significance of hepatitis B core antibody as the only marker of hepatitis B virus infection in high risk patients. Iranian Journal of Pathology, 2009. 4(2): p. 80-84.
155. Nemati, E., et al., Hepatitis C virus infection among patients on hemodialysis: a report from a single center in Iran. Saudi J Kidney Dis Transpl, 2009. 20(1): p. 147-53.
156. Eslamifar, A., et al., Hepatitis G virus exposure in dialysis patients. International urology and nephrology, 2007. 39(4): p. 1257-1263.
157. Toosi, M.N., et al., Risk factors and seroprevalence of hepatitis B and C infections among hemodialysis patients in Tehran. Iranian Journal of Pathology, 2007. 2(4): p. 181-6.
158. Alavian, S.M., et al., Prevalence of hepatitis C virus infection and related risk factors among Iranian haemodialysis patients. Nephrology, 2003. 8(5): p. 256-260.
159. Broumand, B., et al., Prevalence of hepatitis C infection and its risk factors in hemodialysis patients in tehran: preliminary report from "the effect of dialysis unit isolation on the incidence of hepatitis C in dialysis patients" project. Saudi J Kidney Dis Transpl, 2002. 13(4): p. 467-72.
160. Samimi Rad, K., et al., Hepatitis C virus infection among multi-transfused patients and personnel in haemodialysis units in central Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2012.
161. Mobaien, A., et al., Hepatitis E virus seroprevalence in haemodialysis patients in Zanjan Province, Islamic Republic of Iran. Eastern Mediterranean Health Journal, 2013.
162. Torabi, S., et al., Prevalence of hepatitis B, C and HIV in hemophiliac patients of East Azarbaijan in 2004. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2006. 2(7): p. 291-299.
163. Khamisipour, G. and R. Tahmasebi, Prevalence of HIV, HBV, HCV and syphilis infection in high risk groups of Bushehr Province, 1999. Iranian South Medical Journal, 2000. 1(3): p. 53-9.
164. Karimi, M., et al., Inherited coagulation disorders in southern Iran. Haemophilia, 2002. 8(6): p. 740-744.
165. Karimi, M. and A.A. Ghavanini, Seroprevalence of HBsAg, anti-HCV, and anti-HIV among haemophiliac patients in Shiraz, Iran. Haematologia (Budap), 2001. 31(3): p. 251-5.
166. Mansour-Ghanaei, F., et al., Prevalence of hepatitis B and C seromarkers and abnormal liver function tests among hemophiliacs in Guilan (northern province of Iran). Medical Science Monitor, 2002. 8(12): p. CR797-CR800.
167. Esfahani, H. and H. Bazmamoun, The prevalence of blood-borne viral infection (HBV, HCV, HIV) among hemophilia patients in Hamedan province of Iran. Iranian Journal of Blood and Cancer, 2014. 6(4): p. 209-211.
168. Alizadeh, M., Frequencies of hepatitis B and C infections in hemophiliacs. Pejouhesh dar Pezeshki (Research in Medicine), 2006. 30(2): p. 119-123.
169. Naini, M.M., et al., Analysis of the related factors in hepatitis C virus infection among hemophilic patients in Isfahan, Iran. Hepat Mon, 2007. 7(2): p. 59-62.
170. Yazdani, M.R., et al., Hepatitis C virus infection in patients with hemophilia in Isfahan, Iran. International journal of preventive medicine, 2012. 3(Suppl1): p. S89.
171. Zahedi, M.J. and M.S. Darvish, Frequency of Hepatitis B and C infection among Hemophiliac patients in Kerman. Journal of Kerman University of Medical Sciences, 2004.
172. Ziaee, M., et al., Prevalence Of HCV Infection And Related Viremia In Hemophilic Patients Registered In Khorasan Hemophilia Society. The Horizon of Medical Sciences, 2005. 11(3): p. 54-60.
173. Ziaee, M., M.H. Namaei, and G. Azarkar, The prevalence of HTLV-1 and its co-infection with HCV, HBV and HIV in hemophilic patients. Pakistan journal of medical sciences, 2015. 31(5): p. 1246.
174. Ziaee, M., et al., Evaluation of HGV viremia prevalence and its co-infection with HBV, HCV, HIV and HTLV-1 in hemophilic patients of Southern Khorassan, Iran. Hepat Mon, 2007. 7(1): p. 11-4.
175. Ghafourian-Boroujerdnia, M., M.A. Assarehzadegan, and K. Zandian, Hepatitis B and C infections and different genotypes of HCV among sickle cell anemia patients in Ahvaz, South-Western Iran. Jundishapur Journal of Microbiology, 2013. 6(5).
176. Assarehzadegan, M.A., M.G. Boroujerdnia, and K. Zandian, Prevalence of hepatitis B and C infections and HCV genotypes among haemophilia patients in ahvaz, southwest iran. Iranian Red Crescent Medical Journal, 2012. 14(8): p. 470.
177. Samimi-Rad, K. and B. Shahbaz, Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. Haemophilia, 2007. 13(2): p. 156-63.
178. Mahdaviani, F., S. Saremi, and M. Rafiei, Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon) 2008. 4(5): p. 313-322.
179. Sharifi-Mood, B., et al., Viral infection among patients with hemophilia in the Southeast of Iran. J Med Sci, 2006. 6(2): p. 225-8.
180. Sharifi-Mood, B., et al., Hepatitis B and C virus infections in patients with hemophilia in Zahedan, southeast Iran. Saudi medical journal, 2007. 28(10): p. 1516-1519.
181. Lak, M., F. Peyvandi, and P. Mannucci, Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. British journal of haematology, 2000. 111(4): p. 1236-1239.
182. Alavian, S., A. Ardeshir, and B. Hajarizadeh, Seroprevalence of anti-HCV among Iranian hemophilia patients. TRANSFUSION TODAY-GRONINGEN-, 2001: p. 4-4.
183. Abdollahi, A., et al., Seroprevalence of human immunodificiency virus (HIV) and hepatitis C infection in hemophilic patients in Iran. Iranian Journal of Pathology, 2008. 3(3): p. 119-124.
184. Mousavian, S., et al., Seroprevalence of hepatitis C in hemophilia patients refering to Iran Hemophilia Society Center in Tehran. Govaresh, 2011. 16(3): p. 169-174.
185. Javadzadeh, S.H., et al., Study of the prevalence of Hepatitis B, C and HIV infection in Hemophilia and Thalassemia population of Yazd. The Scientific Journal Of Iranian Blood Transfusion Organization (Khoon), 2006. 2(7): p. 315-322.
186. Mobini, G., et al., Prevalence of anti-HCV antibody and related risk factors among bleeding disorder patients in Yazd province of Iran. Journal of Shahrekord Uuniversity of Medical Sciences, 2010. 12(3): p. 36-42.
| Files | ||
| Issue | Vol 7 No 1 (2021) | |
| Section | Review Article(s) | |
| DOI | https://doi.org/10.18502/jbe.v7i1.6298 | |
| Keywords | ||
| Hepatitis C Iran Prevalence Epidemiology Systematic Review | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
molaei alireza, Gholami-Fesharaki M. Epidemiology of Hepatitis C Virus in Iranian Thalassemic, Hemodialysis and Hemophiliac Patients: A Meta-Analysis Study. JBE. 2021;7(1):86-107.
